Cook Biotech focuses on advanced tissue-repair products from biomaterials. The acquisition will bolster RTI Surgical’s place as a contract development and manufacturing organization in regenerative medicine.
Cook Biotech’s portfolio leverages the regenerative properties of porcine small intestinal submucosa. Its biomaterials have been used for areas including nerve repair and cardiovascular care.
RTI Surgical’s products have been used for spine and orthopedic applications, along with dental and urology cases.
The transaction is expected to close in the first quarter of this year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.